Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives
Abstract
Evaluation of axial properties including preparation, surface functionalization, and pharmacokinetics for delivery of pharmacologically active molecules and genes lead to pharmaceutical development of liposome in cancer therapy. Here, analysis of effects of the axial properties of liposome based on cancer treatment modalities as individually and coherently is vital and shows deserving further investigation for the future. In this review, recent progress in the analysis of preparation approaches, optimizing pharmacokinetic parameters, functionalization and targeting improvement and modulation of biological factors and components resulting in a better function of liposome in cancer for drug/gene delivery and immunotherapy are discussed. Here, recent developments on liposome with vaccines and immunoadjuvant carriers, and antigen-carrier system to cancer immunotherapy are introduced.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Liposomal structures can easily load mRNA and DNA, but are not efficient in delivering these therapeutic substances to target cells.
“Although liposomal structures can easily load mRNA and DNA, they are not efficient in delivering these therapeutic substances to target cells [112].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [112]
The citation lists haven’t been fetched yet
References 212 · Cited by 87
- Authors
- Kiaie, S. H., Mojarad-Jabali, S., Khaleseh, F., Allahyari, S., Taheri, E., Zakeri-Milani, P., & Valizadeh, H.
- Affiliations
- Tabriz University of Medical Sciences (IR)
- Corresponding author
- Valizadeh, Hadi
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 581
- Pages
- 119269
- ISSN
- 0378-5173 (ISSN-L)
- OpenAlex
- W3013259145
- Cited by
- 87
- References
- 212
- Citations by year
- 2026: 1 · 2025: 14 · 2024: 12 · 2023: 16 · 2022: 18 · 2021: 20 · 2020: 6
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tabriz University of Medical Sciences
- Tabriz University
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- liposomes, cancer therapy, liposome preparation, surface functionalization, pharmacokinetics, targeted drug delivery, gene delivery, immunotherapy, cancer vaccines, immunoadjuvant
- MeSH terms
- Adjuvants, Immunologic, Animals, Antineoplastic Agents, Disease Models, Animal, Drug Carriers, Drug Compounding, Humans, Liposomes, Neoplasms, Genetic Therapy, Randomized Controlled Trials as Topic, Treatment Outcome, Gene Transfer Techniques, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
